Starling Oncology (STLNW) Other Non-Current Assets (2019 - 2026)

Starling Oncology (STLNW) has reported Other Non-Current Assets for 8 consecutive years, with $657000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets rose 12.12% year-over-year to $657000.0; the trailing twelve-month figure through Jun 2026 stood at $657000.0 (up 12.12% YoY), and the FY2025 full-year result was $606000.0, up 2.89% from the prior year.
• Other Non-Current Assets improved to $657000.0 in Q2 2026 per STLNW's latest filing, from $620000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $875000.0 in Q1 2022 and bottomed at $407000.0 in Q2 2022.
• Historically, Other Non-Current Assets has averaged $577666.7 across 5 years, with a median of $584000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 45.49% in 2022, then surged 36.86% in 2023.
• Over 5 years, Other Non-Current Assets stood at $477000.0 in 2022, then advanced by 17.61% to $561000.0 in 2023, then advanced by 4.99% to $589000.0 in 2024, then gained by 2.89% to $606000.0 in 2025, then increased by 8.42% to $657000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $657000.0, $620000.0, and $606000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.